This phase II study (NCT01693068) aimed to confirm the efficacy and safety of pimasertib at the RP2D in patients with NRAS-mutated cutaneous melanoma, and to compare this with DTIC, the SOC at the time of study initiation. Here, NRAS is linked to cutaneous melanoma.